サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1568024

抗利尿薬の世界市場

Antidiuretic Drugs

出版日
ページ情報
英文 178 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.63円
抗利尿薬の世界市場
出版日: 2024年10月11日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 178 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

抗利尿薬の世界市場は2030年までに11億米ドルに達する見込み

2023年に4億7,940万米ドルと推定される抗利尿薬の世界市場は、2030年には11億米ドルに達し、分析期間2023～2030年のCAGRは11.9%で成長すると予測されます。本レポートで分析したセグメントの1つであるバソプレシン医薬品は、CAGR 11.3%を記録し、分析期間終了時には6億4,270万米ドルに達すると予測されます。オキシトシン医薬品セグメントの成長率は、分析期間中CAGR 14.5％と推定されます。

米国市場は1億3,060万米ドルと推定、中国はCAGR16.0％で成長予測

米国の抗利尿薬市場は2023年に1億3,060万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGR16.0％を牽引し、2030年までに2億2,710万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ9.0%と10.3%と予測されています。欧州では、ドイツがCAGR約9.4%で成長すると予測されています。

世界の抗利尿薬市場- 主要動向と促進要因のまとめ

抗利尿薬が体液バランス障害の治療において重要性を増している理由とは？

抗利尿薬は、バソプレッシンアナログまたは抗利尿ホルモン（ADH）薬としても知られ、尿産生を減少させ、腎臓での水分再吸収を促進することにより、体内の水分バランスを調整する医薬品の一種です。これらの薬剤は、視床下部で産生され下垂体に貯蔵される天然ホルモンであるバソプレシンの作用を模倣したもので、体内の水分レベルを制御することにより恒常性の維持に重要な役割を果たしています。抗利尿薬の主な目的は、バソプレシンの不足または不感受性により、過剰な排尿と喉の渇きを特徴とする疾患である糖尿病性消耗性疾患など、身体が水分を十分に保持できない状態を管理することです。また、夜尿症（おねしょ）、ある種の多尿（尿量の増加）、場合によっては低ナトリウム血症（血中ナトリウム濃度の低下）の治療にも、水分貯留を調節することにより使用されます。最も一般的に使用される抗利尿薬はデスモプレシンであり、バソプレシンの合成アナログで、腎臓に選択的に作用して水分の再吸収を増加させ、尿量を減少させる。この標的作用により、抗利尿薬は体液バランスの回復と脱水の予防において非常に貴重な存在となり、水分代謝に関連する急性および慢性疾患の管理に大きなメリットをもたらします。

抗利尿薬は様々な病状にどのような影響を与えますか？

抗利尿薬は、主に水分の過剰な喪失や滞留が深刻な健康リスクをもたらす、水分不均衡に関連する疾患に対して、幅広い治療効果を発揮します。その最も顕著な用途の一つは、バソプレシンのレベルが不十分であったり、バソプレシンに対する反応が低下しているために、体が水分を保存することができない糖尿病性不眠症の治療です。このような状態では、デスモプレシンなどの抗利尿薬は、過剰な尿量を大幅に減少させるために極めて重要であり、それによって適切な水分補給を維持し、電解質不均衡などの合併症を予防するのに役立ちます。さらに、これらの薬剤は、夜間の尿量を減らし、夜間を通して尿を保持する能力を向上させることによって、特に小児の夜尿症の管理に使用されます。脳損傷、下垂体障害、ある種の遺伝的症候群に関連することが多い多尿・多飲（口渇過多）の場合、抗利尿薬は尿量を正常化し、症状を緩和するのに役立ちます。これらの主な用途以外にも、抗利尿薬は、血液中のナトリウム濃度が低くなると重篤な神経症状を引き起こす低ナトリウム血症の治療に使用されることがあります。このような場合、これらの薬剤を慎重に投与することで、水分貯留による希釈効果を補正し、ナトリウム濃度を安定させ、発作や脳浮腫などの合併症を予防することができます。抗利尿薬の多用途性は周術期管理にも及んでおり、外科手術の現場ではバソプレシンの止血作用を利用して過剰出血を抑制するために使用されています。体液バランス障害の理解が進むにつれて、これらの薬剤の臨床応用は拡大し続けており、体内の水分恒常性を管理するための治療レジメンの不可欠な一部となっています。

抗利尿薬が臨床にもたらす課題とは？

抗利尿薬は、その治療的価値にもかかわらず、特に投与量、潜在的な副作用、患者固有の反応に関して、臨床現場においていくつかの課題を提示しています。主な問題の1つは、特に電解質バランスがすでに低下している患者において、低ナトリウム血症を発症するリスクです。低ナトリウム血症は、抗利尿薬の過剰補正または不適切な投与によって生じる可能性があり、水分貯留や血中ナトリウム濃度の危険な低値につながります。このリスクは、高齢者や心血管疾患、腎疾患のある患者で高くなるため、治療中は血清電解質の綿密なモニタリングが必要となります。夜尿症や糖尿病性不育症のような疾患の管理には、これらの薬剤の長期使用が必要となることが多いため、特に小児や老人の集団では、服薬アドヒアランスの確保がもう一つの課題となります。小児の鼻腔スプレー投与の不便さや経口製剤のコンプライアンスの問題は、効果的な治療結果を妨げる可能性があります。さらに、デスモプレシンは有効ではあるが治療指数が狭いため、投与量のわずかな変動が臨床効果に大きな変化をもたらす可能性があり、副作用を避けるためには正確な投与が重要です。また、頻脈性の問題もあり、長期間にわたって薬剤を繰り返し使用すると反応が減弱し、同じ治療効果を得るためにはより高用量が必要となります。さらに、ある種の抗利尿薬は、止血作用のために血栓塞栓症の既往歴のある患者や血液凝固障害のリスクのある患者には禁忌であり、これらの集団での使用を複雑にしています。最後に、地域によっては費用が高く、入手可能な薬剤が限られているため、これらの薬剤を入手する際の障壁となり、患者のケアに影響を及ぼす可能性があります。これらの課題に対処するためには、患者の全体的な健康状態を注意深く考慮し、定期的なモニタリングを行い、個々の反応や危険因子に基づいて治療法を調整するなど、個別化された治療アプローチが必要となります。

抗利尿薬市場の成長を促す要因は何か？

抗利尿薬市場の成長は、主に糖尿病性不定愁訴、夜尿症、その他の体液バランス障害の有病率の上昇、およびこれらの疾患に対する認識と診断の高まりなど、いくつかの要因によって牽引されています。ヘルスケア専門家が複雑な内分泌疾患や腎疾患の認識と管理に習熟するにつれ、抗利尿薬のような標的治療薬に対する需要が増加しています。診断ツールの進歩やより正確なバイオマーカーの開発も、これらの疾患の早期かつ正確な特定に貢献しており、それによって治療対象が拡大しています。もう一つの重要な成長要因は、心不全、慢性腎臓病、加齢に伴うホルモンバランスの乱れなど、水のホメオスタシスを乱す疾患に罹患しやすい老年人口の拡大です。これらの疾患の罹患率の増加は、抗利尿薬のような効果的な管理ソリューションの需要を加速させています。さらに、長時間作用型で患者に優しいデリバリーシステム（経口溶錠や皮下注射など）の開発など、ドラッグ製剤の技術的進歩が服薬アドヒアランスと治療成績を向上させ、市場成長を後押ししています。製薬業界は抗利尿薬の適応拡大に注力し、術後の水分管理や抗利尿ホルモン不適正分泌症候群（SIADH）の併用療法など、新たな治療領域での使用を模索しており、市場の潜在力をさらに高めています。さらに、特にヘルスケア・インフラが急速に発展しているアジア太平洋地域では、研究開発への投資が拡大しており、改良型の新薬の導入が加速すると予想されます。また、ジェネリック医薬品やバイオシミラーが利用可能になったことで、これらの治療がより身近なものとなり、世界の普及が進んでいます。患者の意識と診断能力が進化し続ける中、抗利尿薬市場は、体液平衡障害に罹患している人々のQOLを改善できる、安全で効果的な標的治療の必要性により、力強い成長の態勢を整えています。

調査対象企業の例（全37件）

  • American Remedies Healthcare Private Limited
  • Amneal Pharmaceuticals, Inc.
  • Apotex, Inc.
  • Azevan Pharmaceuticals, Inc.
  • Bachem AG
  • Baxter International, Inc.
  • BCN Peptides S.A.
  • Ferring International Center SA
  • Fresenius Kabi USA
  • Hybio Pharmaceutical Co., Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP24063

Global Antidiuretic Drugs Market to Reach US$1.1 Billion by 2030

The global market for Antidiuretic Drugs estimated at US$479.4 Million in the year 2023, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 11.9% over the analysis period 2023-2030. Vasopressin Drugs, one of the segments analyzed in the report, is expected to record a 11.3% CAGR and reach US$642.7 Million by the end of the analysis period. Growth in the Oxytocin Drugs segment is estimated at 14.5% CAGR over the analysis period.

The U.S. Market is Estimated at US$130.6 Million While China is Forecast to Grow at 16.0% CAGR

The Antidiuretic Drugs market in the U.S. is estimated at US$130.6 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$227.1 Million by the year 2030 trailing a CAGR of 16.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.0% and 10.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.4% CAGR.

Global Antidiuretic Drugs Market - Key Trends and Drivers Summarized

Why Are Antidiuretic Drugs Becoming Increasingly Vital in Treating Fluid Balance Disorders?

Antidiuretic drugs, also known as vasopressin analogs or antidiuretic hormone (ADH) medications, are a class of pharmaceuticals that help regulate fluid balance in the body by reducing urine production and promoting water reabsorption in the kidneys. These drugs mimic the action of the natural hormone vasopressin, which is produced by the hypothalamus and stored in the pituitary gland, playing a critical role in maintaining homeostasis by controlling water levels in the body. The primary purpose of antidiuretic drugs is to manage conditions where the body cannot adequately retain water, such as in diabetes insipidus, a disorder characterized by excessive urination and thirst due to a lack of or insensitivity to vasopressin. They are also used to treat nocturnal enuresis (bedwetting), certain types of polyuria (increased urine production), and, in some cases, hyponatremia (low blood sodium levels) by regulating water retention. The most commonly used antidiuretic drug is desmopressin, a synthetic analog of vasopressin that selectively acts on the kidneys to increase water reabsorption, thereby reducing urine volume. This targeted action makes antidiuretic drugs invaluable in restoring fluid balance and preventing dehydration, offering significant benefits in managing both acute and chronic conditions related to water metabolism.

How Do Antidiuretic Drugs Impact Various Medical Conditions?

Antidiuretic drugs have a broad therapeutic impact, primarily in managing disorders related to water imbalance, where either excessive loss or retention of fluids poses serious health risks. One of their most prominent uses is in the treatment of diabetes insipidus, where the body is unable to conserve water due to insufficient levels of vasopressin or a reduced response to the hormone. In this condition, antidiuretic drugs such as desmopressin are crucial in significantly reducing the excessive urine output, thereby helping maintain proper hydration and preventing complications like electrolyte imbalances. Additionally, these drugs are employed in managing nocturnal enuresis, particularly in children, by reducing nighttime urine production and improving the child’s ability to hold urine through the night. In the context of polyuria and polydipsia (excessive thirst), conditions often associated with brain injuries, pituitary disorders, or certain genetic syndromes, antidiuretic medications help normalize urine output and alleviate symptoms. Beyond these primary uses, antidiuretic drugs are sometimes used to treat hyponatremia, a condition in which low sodium levels in the blood can lead to severe neurological symptoms. In such cases, careful administration of these drugs can help correct the dilutional effect caused by water retention, stabilizing sodium levels and preventing complications such as seizures and cerebral edema. The versatility of antidiuretic drugs extends to perioperative management as well, where they are used to control excessive bleeding by leveraging vasopressin’s hemostatic properties in surgical settings. As the understanding of fluid balance disorders expands, the clinical applications of these drugs continue to grow, making them an integral part of therapeutic regimens for managing water homeostasis in the body.

What Challenges Do Antidiuretic Drugs Pose in Clinical Practice?

Despite their therapeutic value, antidiuretic drugs present several challenges in clinical practice, particularly concerning their dosing, potential side effects, and patient-specific responses. One of the main issues is the risk of developing hyponatremia, especially in patients with an already compromised electrolyte balance. Hyponatremia can result from overcorrection or inappropriate dosing of antidiuretic drugs, leading to water retention and dangerously low sodium levels in the blood. This risk is heightened in elderly patients and those with cardiovascular or renal conditions, necessitating close monitoring of serum electrolytes during treatment. Another challenge is ensuring adherence, especially in pediatric or geriatric populations, as the management of conditions like nocturnal enuresis or diabetes insipidus often requires long-term use of these medications. The inconvenience of nasal spray administration in children or compliance issues with oral formulations can hinder effective treatment outcomes. Additionally, desmopressin, while effective, has a narrow therapeutic index, meaning that small variations in dose can lead to significant changes in clinical effects, making precise dosing crucial to avoid adverse reactions. There is also the issue of tachyphylaxis, where repeated use of the drug over time leads to a diminished response, requiring higher doses to achieve the same therapeutic effect. Furthermore, certain antidiuretic drugs are contraindicated in patients with a history of thromboembolic events or those at risk of clotting disorders due to their hemostatic effects, complicating their use in these populations. Finally, high costs and limited availability in some regions can pose barriers to accessing these medications, impacting patient care. Addressing these challenges requires a personalized approach to treatment, with careful consideration of the patient’s overall health status, regular monitoring, and adjustments to therapy based on individual responses and risk factors.

What Factors Are Driving the Growth of the Antidiuretic Drug Market?

The growth in the antidiuretic drug market is driven by several factors, primarily the rising prevalence of diabetes insipidus, nocturnal enuresis, and other fluid balance disorders, along with the increasing awareness and diagnosis of these conditions. As healthcare professionals become more adept at recognizing and managing complex endocrine and renal disorders, the demand for targeted therapies like antidiuretic drugs is on the rise. Advances in diagnostic tools and the development of more precise biomarkers have also contributed to earlier and more accurate identification of these conditions, thereby expanding the treatment population. Another critical growth driver is the expanding geriatric population, which is more susceptible to conditions that disrupt water homeostasis, such as heart failure, chronic kidney disease, and age-related hormonal imbalances. The increased incidence of these conditions has spurred demand for effective management solutions like antidiuretic drugs. Moreover, technological advancements in drug formulations, such as the development of longer-acting and more patient-friendly delivery systems (e.g., oral melt tablets and subcutaneous injections), are improving adherence and therapeutic outcomes, thereby boosting market growth. The pharmaceutical industry’s focus on expanding indications for antidiuretic drugs, exploring their use in new therapeutic areas such as postoperative fluid management and in combination therapies for syndrome of inappropriate antidiuretic hormone secretion (SIADH), is further enhancing their market potential. Additionally, growing investments in research and development, particularly in the Asia-Pacific region, where healthcare infrastructure is rapidly advancing, are expected to accelerate the introduction of new and improved drug variants. The availability of generics and biosimilars is also making these treatments more accessible, thereby increasing their adoption globally. As patient awareness and diagnostic capabilities continue to evolve, the antidiuretic drug market is poised for robust growth, driven by the need for safe, effective, and targeted therapies that can improve quality of life for individuals affected by fluid balance disorders.

Select Competitors (Total 37 Featured) -

  • American Remedies Healthcare Private Limited
  • Amneal Pharmaceuticals, Inc.
  • Apotex, Inc.
  • Azevan Pharmaceuticals, Inc.
  • Bachem AG
  • Baxter International, Inc.
  • BCN Peptides S.A.
  • Ferring International Center SA
  • Fresenius Kabi USA
  • Hybio Pharmaceutical Co., Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Antidiuretic Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Incidence of Diabetes Insipidus Drives Demand for Antidiuretic Medications
    • Increasing Prevalence of Nocturia Expands Market Potential for Antidiuretic Therapies
    • Rising Geriatric Population Propels Demand for Antidiuretic Drugs in Age-Related Disorders
    • Advancements in Drug Formulations Spur Growth in Long-Acting Antidiuretic Products
    • Increasing Focus on Pediatric Care Boosts Adoption of Pediatric-Specific Antidiuretic Medications
    • Growing Awareness of Urinary Disorders Creates Opportunities for Market Growth
    • Innovation in Delivery Mechanisms Propels Adoption of Injectable and Nasal Spray Formats
    • Shift Towards Personalized Medicine Sustains Demand for Targeted Antidiuretic Therapies
    • Rising Adoption in the Treatment of Chronic Kidney Diseases Expands Market Reach
    • Parental Concerns Over Enuresis in Children Drive Demand for Effective Antidiuretic Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antidiuretic Drugs Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antidiuretic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antidiuretic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Antidiuretic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Vasopressin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Vasopressin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Vasopressin Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Oxytocin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Oxytocin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Oxytocin Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Desmopressin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Desmopressin Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Desmopressin Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 15: USA Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 16: USA 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 17: Canada Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 18: Canada Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 19: Canada 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • JAPAN
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 20: Japan Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Japan Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 22: Japan 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • CHINA
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 23: China Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 24: China Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 25: China 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • EUROPE
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 26: Europe Recent Past, Current & Future Analysis for Antidiuretic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 27: Europe Historic Review for Antidiuretic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 28: Europe 16-Year Perspective for Antidiuretic Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • FRANCE
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 32: France Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: France Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 34: France 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • GERMANY
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 35: Germany Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Germany Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 37: Germany 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 38: Italy Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Italy Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 40: Italy 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 41: UK Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 42: UK Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 43: UK 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 44: Spain Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Spain Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 46: Spain 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 47: Russia Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Russia Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 49: Russia 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 50: Rest of Europe Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Rest of Europe Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 52: Rest of Europe 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 53: Asia-Pacific Recent Past, Current & Future Analysis for Antidiuretic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 54: Asia-Pacific Historic Review for Antidiuretic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 55: Asia-Pacific 16-Year Perspective for Antidiuretic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 59: Australia Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Australia Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 61: Australia 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • INDIA
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 62: India Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: India Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 64: India 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 65: South Korea Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 66: South Korea Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 67: South Korea 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 68: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Rest of Asia-Pacific Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 70: Rest of Asia-Pacific 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 71: Latin America Recent Past, Current & Future Analysis for Antidiuretic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 72: Latin America Historic Review for Antidiuretic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 73: Latin America 16-Year Perspective for Antidiuretic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 77: Argentina Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Argentina Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 79: Argentina 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 80: Brazil Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Brazil Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 82: Brazil 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 83: Mexico Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Mexico Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 85: Mexico 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 86: Rest of Latin America Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Rest of Latin America Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 88: Rest of Latin America 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 89: Middle East Recent Past, Current & Future Analysis for Antidiuretic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 90: Middle East Historic Review for Antidiuretic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 91: Middle East 16-Year Perspective for Antidiuretic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 95: Iran Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Iran Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 97: Iran 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 98: Israel Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Israel Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 100: Israel 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 101: Saudi Arabia Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Saudi Arabia Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 103: Saudi Arabia 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 104: UAE Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UAE Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 106: UAE 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 107: Rest of Middle East Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Middle East Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Middle East 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030
  • AFRICA
    • Antidiuretic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 110: Africa Recent Past, Current & Future Analysis for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Africa Historic Review for Antidiuretic Drugs by Drug Type - Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
    • TABLE 112: Africa 16-Year Perspective for Antidiuretic Drugs by Drug Type - Percentage Breakdown of Value Sales for Vasopressin Drugs, Oxytocin Drugs and Desmopressin Drugs for the Years 2014, 2024 & 2030

IV. COMPETITION